We are advising Azenta, Inc., a leading provider of life sciences solutions worldwide, on the acquisition of B Medical Systems SARL for an initial purchase price of €410 million, increasing to a maximum of €460m subject to an earn-out. The transaction is due to complete in October 2022.
Based in Massachusetts and listed on Nasdaq, Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally.
B Medical Systems is a manufacturer and global provider of a portfolio of products that includes vaccine transport cold chain equipment, medical refrigeration, blood management solutions based in Luxembourg.
This acquisition complements Azenta's cold chain capabilities, adding differentiated solutions for reliable and traceable transport of temperature-sensitive specimens.
Commenting on the transaction, corporate partner Will Belcher said: "As a firm, we are proud to advise leading businesses in the life sciences sector like Azenta. It has been a pleasure supporting them on this significant acquisition."
John O'Brien, Azenta’s Senior Vice President, Corporate Development added: "We are very grateful to Taylor Wessing for the exceptional support they have provided throughout this complex deal. The team's European M&A expertise in this sector has been invaluable in delivering this result."
The team was led by partner Will Belcher and senior associate Bryce Bartlett, with support from senior associate Will Zhang, associates Sophie Weavers and Stephanie Russell (corporate), partner Graham Samuel-Gibbon and senior associate Sally Robertson (tax & incentives), partner Fiona Coady and senior associate Kate Bowden (banking & finance), and partner Paolo Palmigiano (competition, trade and foreign investment).
The seller is being advised by Hogan Lovells LLP in Singapore.
